MacroGenics MGC026 trial advances to stage 2 in head and neck cancer

July 23, 2026 4:01 PM

MacroGenics, Inc. (NASDAQ: MGNX) provided an update on its ongoing Phase 1 study of MGC026, a B7-H3-directed antibody-drug conjugate (ADC) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found